Christopher Hergott

“We stole all your knowledge and art, and now we’re gonna put a meter on it and sell it back to you. You’re welcome.”

exphem.org/article/S0301-… Important pub from @TrowbridgeLab for those whose institutions shift to X-ray source for BMT conditioning , published in @ISEHSociety journal Exp Hem. You can’t simply give apparent equivalent doses of gamma and x-ray and get the same outcome.

Our newest preprint is now online! We lift up the hood on TET2 mutant clonal hematopoiesis and show that oxidative metabolism is a critical feature of TET2 deficient HSPC - with compensatory redox control as a potential vulnerability. biorxiv.org/content/10.648…

Happy to see this out. Co-led with @petergkim at @CellChemBiol. #EvansMDS @bloodcancerutd #leusm #clonalhematopoiesis @DanaFarber @MGBpathology Metabolic control of innate immune activation in TET2-mutant clonal hematopoiesis: Cell Chemical Biology cell.com/cell-chemical-…

This research starts with understanding the “why.” ❤️ With support from one of our early career scientist grants, Dr. Zuzana Tothova is studying how changes inside blood cells can lead to blood cancers like myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). A better understanding of the earliest blood cell changes leading to cancer will help scientists find better, more targeted ways to treat it 👉 bit.ly/4qAqYOH

Turns out Sean McDermott’s best trait as a Bills coach was protecting everyone from Terry Pegula. A true defensive genius.

New paper in @CellChemBiol from Starczynowski Lab → congrats to first author Emma Uible (@emmavontz)! "CASP1 is a non-enzymatic dependency in MDS/AML that restrains excessive inflammatory signaling" sciencedirect.com/science/articl…

PSA: Stop calling macrophages in tissue M1 or M2. These are not states that exist in biology. The only use of M1 is a macrophage cultured ex vivo with LPS and IFNg; and for M2: IL-4/13/10. Macrophages in tissues are highly complex and diverse and do not resemble either of the aforementioned M1/M2 states. M1/M2 language causes confusion and sets the field back. Refer to your macrophages by the molecules they express and the cytokines they make.

Amen

This would force everyone to either: A) Do residency in a specialty covered in core rotations, or B) Apply to residency with minimal (elective) experience in field of interest, no?

Check out our study on the genomic features of pediatric CTCL, published @ModernPathology We found recurrent TK gene fusions including JAK2 in most mycosis fungoides, TYK2 in LyP and pcALCL, some novel fusions. #hemepath #pedipath #pathx Free link: authors.elsevier.com/a/1l%7ErV3B8d9…

#InflammasomePower! How is NLPR3 primed & activated in chronic non-communicable inflammatory diseases? With Oceane &co we show that chronic oxPAPC signaling drives NRF2 activation that primes & activates NLRP3 sustaining #atherosclerosis in mice & humans! biorxiv.org/cgi/content/sh…

👀👀 Revumenib now FDA approved for NPM1 mutated relapsed AML #amlsm

Here's a high-resolution peek at #neutrophils isolated straight from the human bloodstream, captured in stunning detail with #electronmicroscopy and colorized! 🤩 #MicroscopyMonday

Project EVOLVE: an international analysis of postimmunotherapy lineage switch, an emergent form of relapse in leukemia ashpublications.org/blood/article/… 70 cases of B-cell #ALL with lineage switch after immunotherapy (anti-CD19) to AML or mixed phenotypic leukemia. Dismal outcome with median OS 4.9 months. #leusm @BloodPortfolio

With the disappointing announcement today by @abbvie of the negative result of the VERONA venetoclax/azacitidine trial, that brings the tally to (by my count) 17 consecutive negative randomized drug trials in higher-risk #MDSsm. This is a slide I made summarizing them./1

Long awaited results of #VERONA (PH3 of aza-ven vs aza) in higher risk MDS press release with negative top line results for OS. We unfortunately remain in the dreaded boulevard of broken dreams in higher risk #MDSsm. Subgroup analyses will be important. news.abbvie.com/2025-06-16-Abb…

Between alarms and sheltering, I learned last night that my postdoc mentor, Professor Atul Butte @atulbutte, has passed away, and he is only 55 years old. This is devastating news 💔. Atul was a giant in so many ways. He was a visionary leader in translational bioinformatics @Stanford who reinvented himself as a pioneer of AI in medicine @UCSF. He published hundreds of papers, founded multiple companies, was elected to the National Academy of Medicine, and recently to the American Academy of Arts & Sciences. But Atul was much more than his achievements. He possessed something rare in science - infectious positivity. Every encounter with him, no matter how low I felt going in, I'd leave optimistic and energized to pursue my goals. After every talk he gave, students would line up to tell him how he motivated them to do something big with their lives. Another rare trait was his kindness and generosity with credit. Atul taught me: "credit is indefinitely divisible." In a field where people often take undeserved credit, this was inspiring. I will miss Atul, like so many others will. He is survived by his wife Gini and daughter Kimi, but his legacy will live on through his countless trainees and colleagues worldwide.

Dr. Navin Mahadevan is setting up his new lab at #UMichPath to explore how hidden genes in cancer cells could unlock powerful immune responses. He’s blending basic science with clinical precision, from spatial transcriptomics to molecular diagnostics. 🔗: michmed.org/PYXVx

ICCS has revitalized their YouTube channel and will be releasing a range of #flowcytometry videos for all levels, from beginners to experts. The first video is on tandem dyes: youtube.com/watch?v=5cV7E9… Be sure to like and *subscribe* so that you don't miss new videos! #hemepath